Antihyperlipidemic drugs are expected to treat Alzheimer's disease
April 03, 2019 Source: Science and Technology Daily
Window._bd_share_config={ "common":{ "bdSnsKey":{ },"bdText":"","bdMini":"2","bdMiniList":false,"bdPic":"","bdStyle":" 0","bdSize":"16"},"share":{ }};with(document)0[(getElementsByTagName('head')[0]||body).appendChild(createElement('script')) .src='http://bdimg.share.baidu.com/static/api/js/share.js?v=89860593.js?cdnversion='+~(-new Date()/36e5)];Science and Technology Daily Kunming, April 2 (Reporter Zhao Hanbin) Alzheimer's disease is a common neurodegenerative encephalopathy, and there is currently no effective cure or drug in clinical practice. The reporter learned from the Kunming Institute of Zoology, Chinese Academy of Sciences on the 2nd that the hospital has made important breakthroughs in the treatment of Alzheimer's disease. The relevant results were published in the international journal Autophagy.
The most common clinical manifestations of Alzheimer's disease are progressive memory loss, decreased cognitive ability, and other mentally relevant symptoms such as anxiety. As the aging process intensifies, the number of Alzheimer's patients worldwide is increasing dramatically.
Yao Yonggang, a researcher and author of the Kunming Institute of Zoology, Chinese Academy of Sciences, said that the pathogenesis of Alzheimer's disease is very complicated and is affected by many factors, and dyslipidemia is one of the important risk factors. Studies have shown that excessive production of beta-amyloid and insufficient clearance are key incentives to promote the clearance of this protein or an important strategy for the prevention and treatment of this disease. At the same time, a large number of studies have shown that autophagy dysfunction plays an important role in its pathogenesis, so the induction of autophagy is expected to become a new perspective for the treatment of Alzheimer's disease.
The research team carried out systematic research from various levels such as molecules, cells and mouse animal models. At the cellular level, they found that the US Food and Drug Administration approved a drug for the treatment of hyperlipidemia. The nuclear receptor peroxisome alpha agonist gemfibrozil and pirinic acid activated autophagy and thus beta- Amyloid protein clearance; at the mouse model level, the two drugs can significantly enhance the phagocytosis and degradation of β-amyloid by astrocytes and microglia, thereby improving pathophysiological characteristics and ultimately improving Al The structure and function of damaged neurons in mice with Alzheimer's disease, and significantly improve their learning and memory ability.
The research not only found new targets, but also provided experimental evidence for the treatment of hyperlipidemia drugs for the clinical trial of Alzheimer's disease treatment. It also revealed for the first time the important protective functions of the two drugs in this disease, and further corroborated The core role of microglia and astrocytes in the treatment has opened up new ideas for the prevention and treatment of Alzheimer's disease.
NINGBO VOICE BIOCHEMIC CO. LTD , https://www.medicine-voice.com